StemCells Inc. Announces Simultaneous Publication of Preclinical and Clinical Results of Its Neural Stem Cells for Myelination Disorder

Published: Oct 11, 2012

NEWARK, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the Company's proprietary HuCNS-SCĀ® cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10 edition of Science Translational Medicine, the peer review journal of the American Association for the Advancement of Science (

Back to news